Payment overview · 2025
General Payments
$372.52
22 reported records · 13 companies
Healthcare provider profile · identity verified
William James Phipps, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUTHERLAND, VA · NPI 1285601260
Verified facts
What the public records show
CMS Open Payments records show William James Phipps, MD received $372.52 in general payments during 2025 across 22 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.99 | 16.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.21 | 14.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.07 | 12.9% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.30 | 10.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.81 | 7.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.59 | 6.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.72 | 6.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.83 | 5.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.98 | 4.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.84 | 4.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.47 | 4.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.59 | 3.9% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $13.12 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $372.52 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.99 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.07 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $13.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 343 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 81 |
| Lisinopril | Lisinopril | 297 | 78 |
| Gabapentin | Gabapentin | 296 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 76 |
| Omeprazole | Omeprazole | 277 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 271 | 69 |
| Metformin Hcl | Metformin Hcl | 258 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 66 |
| Losartan Potassium | Losartan Potassium | 215 | 53 |
| Tramadol Hcl | Tramadol Hcl | 215 | 52 |
| Simvastatin | Simvastatin | 211 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 51 |
| Montelukast Sodium | Montelukast Sodium | 199 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 50 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 181 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 44 |
| Furosemide | Furosemide | 174 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 41 |
| Glipizide Er | Glipizide | 155 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 138 | 30 |
| Sertraline Hcl | Sertraline Hcl | 132 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 129 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 29 |
| Prednisone | Prednisone | 124 | 70 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 116 | 24 |
| Azithromycin | Azithromycin | 108 | 91 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 28 |
| Trazodone Hcl | Trazodone Hcl | 103 | 31 |
| Pregabalin | Pregabalin | 90 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 16 |
| Allopurinol | Allopurinol | 78 | 19 |
| Clonazepam | Clonazepam | 77 | suppressed |
| Potassium Chloride | Potassium Chloride | 76 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 14 |
| Glimepiride | Glimepiride | 65 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 50 |
| Levofloxacin | Levofloxacin | 60 | 48 |
| Lorazepam | Lorazepam | 58 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 13 |
| Carvedilol | Carvedilol | 55 | 17 |
| Colchicine | Colchicine | 53 | 23 |
| Ibuprofen | Ibuprofen | 52 | 19 |
| Famotidine | Famotidine | 51 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | 14 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | suppressed |
| Atenolol | Atenolol | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Eliquis | Apixaban | 46 | 16 |
| Spironolactone | Spironolactone | 46 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 22 |
| Meloxicam | Meloxicam | 40 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 12 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Temazepam | Temazepam | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 13 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Nystatin | Nystatin | 19 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $372.52 · 22 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AREXVY, BREZTRI, CeQur Simplicity, Dexcom G6 Transmitter, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, NEXLETOL, OTEZLA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, XIFAXAN, YUPELRI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error